VYDUO (nebivolol hydrochloride; valsartan) by AbbVie is established. Approved for hypertension, to lower blood pressure, to lower blood pressure [see clinical studies ( )] and 2 more indications. First approved in 2022.
Drug data last refreshed 21h ago
established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral…
Worked on VYDUO at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.